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The plant-based compounds rho-iso-alpha acids (RIAA) from Humulus lupulus (hops) and proanthocyanidins (PAC) from Acacia
niloticahavebeenshowntomodulateinsulinsignalinginvitro.Weinvestigatedtheireﬀectsontriglyceride(TG)depositionin3T3-
L1 adipocytes, glucose and insulin in obese mouse models, and metabolic syndrome markers in adults with metabolic syndrome.
The combination of RIAA and PAC synergistically increased TG content and adiponectin secretion in 3T3-L1 adipocytes under
hyperinsulinemic conditions and reduced glucose or insulin in obese mice. In a clinical trial, tablets containing 100mg RIAA and
500mg PAC or placebo were administered to metabolic syndrome subjects (3 tablets/day, n = 35; 6 tablets/day, n = 34; or placebo,
n = 35) for 12 weeks. Compared to placebo, subjects taking 3 tablets daily showed greater reductions in TG, TG : HDL, fasting
insulin, and HOMA scores. The combination of RIAA : PAC at 1 : 5 (wt : wt) favorably modulates dysregulated lipids in insulin
resistance and metabolic syndrome.
1.Introduction
Metabolic syndrome, which aﬀects almost 40% of American
adults [1], is a complex metabolic mosaic of abnormal
lipid, weight, and inﬂammatory markers. These metabolic
abnormalities indicate underlying impairments in cellular
insulin signaling and ultimately result in increased risk
for diabetes or cardiovascular disease [2, 3]. Diet and
exercise modiﬁcation is recommended by American Heart
Association as ﬁrst-line treatment because of their ability to
address one or more components. If lifestyle modiﬁcation
fails due to patient noncompliance, antidiabetic drugs are
often prescribed. However, approximately half of patients
require more than one pharmaceutical agent within three
years of diagnosis, and the proportion increases to 75%
within nine years [4].
The diﬃculty in treating metabolic syndrome and type 2
diabetes may be due to the failure to address underlying
molecular mechanisms of insulin resistance, which remain
not thoroughly understood. A relevant aspect of this
pathology is that even before the development of fasting
or postprandial hyperglycemia, insulin resistance manifests
as abnormalities in triglyceride (TG) storage and lipolysis
in insulin-sensitive tissues, causing disruption of insulin
signaling, leading to activation of NF-κB and the subsequent
upregulation of proinﬂammatory genes [5, 6]. Targeting
kinases related to insulin signaling and inﬂammation and/or
reducing lipid overspill are potentially eﬀective strategies to
treat insulin resistance.
Whereas kinase-inhibiting drugs may eﬀectively com-
pletelyinhibittheseandotherpathwaynetworks,suchstrong
inhibitionhasbeenassociatedwithadverseeventswhenused
for a long duration. It has been shown that some botanical
compounds derived from common foods have kinase-
modulating activity or have insulin-potentiating action,
safely and eﬀectively modifying these interconnecting cellu-
lar pathways that address dysfunctional glucose metabolism,
particularly as they relate to lipotoxicity [7–10]. In addition,2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
they may also assist in peripheral mechanisms related to type
2 diabetes, such as improving lipid metabolism, antioxidant
status, and vasculature [11, 12].
We previously discovered that traditionally consumed
foodstuﬀss u c ha sh o p s( Humulus lupulus L.) and acacia
(Acacia nilotica) have modulating activity on kinases speciﬁc
to insulin function. Speciﬁcally, hops-derived rho-iso-alpha
acids (RIAAs), used as bitter ﬂavoring agents in the beer
industry, dose-dependently reduce GSK-3, PI3K, and PKCβ
activity in cell-free kinase assays [13]. Proanthocyanidin-
(PAC-) rich extract from acacia bark was found to modulate
the aforementioned kinases in addition to IKKβ in a dose-
dependent manner (unpublished). Others have also shown
that PAC from a variety of botanicals improved symptoms of
metabolic syndrome in vivo [14, 15].
In this paper, we report on our identiﬁcation of a speciﬁc
ratio of these natural products that favorably modiﬁed TG
formation in the 3T3-L1 adipocyte model. Beneﬁcial results
with this ratio of actives on serum glucose and insulin in two
diabetic mice models led us to conduct a 12-week clinical
trial in individuals with the metabolic syndrome.
2.MaterialsandMethods
2.1. Chemicals and Reagents. Troglitazone, methylisobutylx-
anthine, dexamethasone, Oil Red O, and insulin were
obtained from Sigma (St. Louis, MO). Penicillin, strepto-
mycin, Dulbecco’s modiﬁed Eagle’s medium (DMEM) were
from Mediatech (Herndon, VA) and 10% HI-FBS (heat
inactivated fetal bovine serum) from Mediatech and Hyclone
(Logan, UT). All standard reagents were obtained from
Sigma and were of the highest purity commercially available.
Hops RIAA and Acacia PAC were provided by Metagenics,
Inc. (Gig Harbor, WA); their chemical structures have been
previously described [16, 17]. Growth medium was made by
adding50mLofHI-FBSand5mLofpenicillin/streptomycin
to 500mL DMEM. This medium was stored at 4◦Ca n d
warmed to 37
◦C in a water bath before use.
2.2. Cell Culture. The murine 3T3-L1 ﬁbroblast cell line
was purchased from American Type Culture Collection
(Manassas, VA) and maintained according to instructions
from the supplier. Preadipocytes were cultured in DMEM
containing 10% HI-FBS, with added 50U penicillin/mL
and 50μg streptomycin/mL, and maintained in log phase
prior to experimental setup. Cells were grown in a 5%
CO2 humidiﬁed incubator at 37
◦C. 3T3-L1 cells were
seeded at an initial density of ∼4 ×104 cells/cm2 in 24-
well plates. For 2 days, the cells were allowed to grow
to reach conﬂuence. To force cells to diﬀerentiate into
adipocytes, medium consisted of 10% FBS/DMEM (high
glucose), 0.5mM methylisobutylxanthine, 0.5μMd e x a m -
ethasone, and 10μg/mL insulin was added. After 3 days,
the medium was changed to postdiﬀerentiation medium
consisting of 10μg/mL insulin in 10% FBS/DMEM.
2.3. Lipogenic Activity in 3T3-L1 Cells. Lipogenesis was
assessed using the preadipocyte diﬀerentiation assay as
described by Xu et al. [18] with the following modiﬁcation:
(1) murine 3T3-L1 preadipocytes were selected rather than
freshly isolated, rat preadipocytes, (2) intracellular lipid
was measured using Oil Red O and BODIPY, and (3)
troglitazone (10μM) was used as the positive control in
place of rosiglitazone. Test material was added in dimethyl
sulfoxide (DMSO) at day 0 of diﬀerentiation and every 2
days throughout the maturation phase (days 6/7). Fresh test
material was added together with fresh media. Intracellular
lipid was assessed using Oil Red O staining according to the
method of Kasturi and Joshi [19]. Results were represented
relative to stained cells in the solvent controls.
2.4. Adiponectin Assay in 3T3-L1 Cells. For anti-inﬂamma-
tory activity, on day 6 after diﬀerentiation, adipocytes were
treated with test material 4 hours before addition of TNF-α
at a ﬁnal concentration of 10ng/mL. Cells were incubated
overnight for approximately 18 h, followed by removal of
the supernatant medium and cell staining for nonpolar
lipid with BODIPY. Adiponectin was quantiﬁed using the
Quantikine Mouse IL-6 Immunoassay kit or the Mouse
Adiponectin Quantikine Immunoassay kit (R&D Systems,
Minneapolis, MN).
2.5. Lipogenic Index, Adiponectin Index, and Synergy Calcu-
lations. For lipogenesis assays, test compounds were each
assayed in duplicate for a minimum of three independent
times. The Lipogenic Index was computed for each sample
bynormalizingOilRedOvaluestothesolventcontrolwithin
eachexperiment.Foradipogenicassays,eachexperimentwas
performed in duplicate. The eﬀect of the test compounds on
adiponectin secretion was computed relative to the solvent
control.
An estimate of the expected eﬀects of the hops RIAA and
acacia PAC combinations was made using the relationship
1/LI = X/LIX + Y/LIY or 1/AI = X/AIX + Y/AIY where LI =
Lipogenic Index, AI = Adiponectin Index, and X and Y were
relative fractions of each component in the test mixture and
X + Y = 1. Synergy was inferred if the mean of the estimated
LI and AI fell below the lower 95% conﬁdence interval of
the estimate of the corresponding observed fraction. This
deﬁnition of synergy was described previously [20].
2.6. In Vivo Study. The eﬀect of test materials on nonfasting
serum glucose and insulin was assessed in the KK-Ay/Ta
and C57BLKS/J-m+/+ Lep rdb (db/db)m o d e l so fn o n -
insulin-dependent diabetes mellitus (NIDDM) and obesity
performed at MDS Pharma Services (Taiwan). Nine-week-
old male KK-Ay/Ta mice, weighing 40±5g,wereprovided
by Clea Inc. (Tokyo, Japan); 9-week-old male db/db mice,
weighing 50±5g, were provided by the Institute for Animal
Reproduction (Ibaraki, Japan). These animals exhibited
hyperinsulinemia, hyperglycemia, and islet atrophy. The
animals were housed in Individually Ventilated Cages Racks
(IVC Racks, 36 Mini Isolator systems) throughout the
experiment. Each APEC cage (in cm, 26.7 length × 20.7
width × 14.0 height) was sterilized with autoclave and
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environment under controlled temperature (22◦–24◦C) and
humidity (60%–70%) with 12-hour light/dark cycle. The
animals were fed sterilized lab chow and sterilized distilled
water ad libitum. All aspects of this work, including housing,
experimentation, and disposal of animals, were performed
in accordance with the Guide for the Care and Use of
Laboratory Animals (National Academy Press, Washington,
D. C., 1996).
Test substances and vehicle (2% Tween 80, Wako, Japan)
were administered orally daily for 3 consecutive days starting
immediately after the pretreatment blood sampling (day
1). Each substance was tested in a group of 5 mice. Post-
treatment blood samples were drawn from the orbital sinus
90 minutes after administration of the ﬁnal dose on day 7.
Serum glucose and insulin levels were determined by enzy-
matic (Mutaratase-GOD, Wako, Japan) and ELISA (mouse
insulin assay kit, SPIbio, France) methods, respectively. Post-
treatment serum glucose and insulin values expressed in
percentage of respective pretreatment values were calculated,
and paired t-test was used for comparison. Diﬀerences were
considered signiﬁcant at P<. 05 level (2-sided).
2.7. Human Clinical Trial. To investigate the eﬀect of
RIAA and PAC (supplemented orally at 1 : 5 wt : wt)
on serum glucose, insulin, and lipids in individuals with
metabolic syndrome, a randomized, 12-week, double-blind,
placebo-controlled trial was conducted at the Functional
Medicine Research Center (Gig Harbor, WA). Inclusion
criteria included, (i) age 18–70 years, (ii) BMI 25–42.5kg/m2
and (iii) TG : HDL-cholesterol ≥3.5; (iv) fasting insulin
≥71.75pmol/L (or 10μIU/mL). In addition, individuals had
to meet 3 of the following 5 criteria: (i) waist circumference
>88.9cm (or 35 inches) for women and >101.6cm (or 40
inches) for men, (ii) TG ≥1.7mmol/L (or 150mg/dL), (iii)
HDL-cholesterol<1.3mmol/L(or50mg/dL)forwomenand
<1.0mmol/L (or 40mg/dL for men, (iv) blood pressure
≥130/85mmHg or diagnosed hypertension on medication,
and (v) fasting glucose ≥5.55mmol/L (or 100mg/dL). Key
exclusion criteria included involvement in a weight loss
program leading to 10% or greater body weight loss over
the preceding 4 weeks, use of blood glucose or cholesterol-
lowering medications or supplements, corticosteroid use
in the preceding 4 weeks, allergy to study materials, or a
history of diabetes, cancer, renal, hepatic, or cardiovascular
diseases. The study was conducted in accordance with the
Declaration of Helsinki, and informed written consent was
obtained from each participant prior to enrollment in
the study.
Eligible participants were randomized to one of 4 arms
using Microsoft Excel 2003 (Redmond, WA): Arm 1: placebo
tablet, 3 times daily; Arm 2: active tablet consisting of hops
100mg RIAA and 500mg acacia PAC (1 : 5), 3 times daily;
Arm 3: same as Arm 2 but at 2 tablets 3 times daily; Arm 4:
placebo tablet, 2 tablets 3 times daily. All participants were
instructed in an hour-long nutritional counseling session
at the start of the study to follow the AHA Step 1 (low-
fat) diet. Caloric prescriptions were determined by analyzing
bioelectrical impedance to calculate basal metabolic rate
(BMR) using the Katch-McArdle formula [21]B M R= 370 +
(21.6 × lean mass in kg). The daily BMR was calculated
by multiplying by an activity factor (1.12 for men and 1.14
for women) derived from the National Academy of Sciences
low activity level (walking 2.2 miles daily) and was based on
150 minutes of aerobic activity per week. Caloric needs were
estimated by subtracting 600 calories from the calculated
BMR.
After the baseline visit, participants returned at 2, 4,
8, and 12 weeks for follow-up visits. Compliance to the
diet and exercise treatment was monitored at each visit
using 3-day diet and exercise diaries. Overnight fasting blood
samples were collected at baseline, 8 weeks and 12 weeks
for lipid analysis. For 2-hour postprandial insulin/glucose
response, participants consumed a solution containing 75g
glucose (Trutol 100, CASCO NERL Diagnostics) after the
fasting blood draw, and 2 hours after the glucose challenge,
blood was drawn and assayed for glucose and insulin levels
(Laboratories Northwest, Tacoma, WA).
2.8. Statistical Analysis. Data from Arm 1 and Arm 4 were
combined and served as one placebo arm. For each variable,
changes from baseline to 8 weeks and 12 weeks were calcu-
lated for each treatment arm. Baseline determinations were
analyzed using one-way ANOVA. Changes from baseline
to 8 weeks and 12 weeks were analyzed separately for
each arm using a priori two-sided paired t-test. Diﬀerences
among treatments were determined by ANOVA with post
hoc multiple comparisons between treatments. All the tests
were 2-sided. The P-value was signiﬁcant if <.05. Data were
analyzed using SAS (version 9.1, Cary, NC).
3. Results
3.1. RIAA and PAC Synergy In Vitro. The murine 3T3-L1
preadipocyte is used to study the potential eﬀects of test
compounds on adipocyte diﬀerentiation and adipogenesis.
Assessing TG synthesis of 3T3-L1 cells provides a validated
model of the insulin-sensitizing capacity of the test agent
[22]. For assessing the eﬀects of hops RIAA and acacia PAC
combination on lipogenesis and adiponectin secretion, the
1-to-5 and 1-to-10 combinations of RIAA : PAC at 50, 10,
5, and 1μg/mL were tested. With respect to increasing lipid
incorporation under the condition of hyperinsulinemia,
RIAA : PAC at 1 : 5 exhibited synergistic eﬀects at all 4
concentrations, while at 1 : 10 the synergy was observed at
5a n d1 0μg/mL (Table 1). Regarding increasing adiponectin
secretion from TNFα stimulation, RIAA : PAC at 1 : 5
exhibited synergy at 1, 5, and 50μg/mL, while at 1 : 10 the
synergy was observed at 1, 10, and 50μg/mL (Table 1).
3.2. RIAA and PAC Combinations on Serum Glucose and
Insulin In Vivo. With the RIAA : PAC at 1 : 5 and 1 : 10
showing synergistic eﬀect on lipogenesis in vitro, we went on
to test the eﬀect of these ingredients (/) with both combined
ratios as well as single ingredients on glucose metabolism
in 2 NIDDM mouse models. Rosiglitazone was used as the
positive control. In KK-Ay/Ta mice, 3 days of RIAA or PAC4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Table 1: Observed and expected lipogenic response elicited by hops RIAA and acacia PAC in the 3T3-L1 model.
RIAA : PAC at 1 : 5 (wt : wt) RIAA : PAC at 1 : 10 (wt : wt)
Lipogenic Index∗ Observed Expected Synergy Observed Expected Synergy
50(μg/mL) 1.05 0.98 Yes 0.99 1.03 No
10 0.96 0.89 Yes 1.00 0.90 Yes
5 0.93 0.90 Yes 1.00 0.90 Yes
1 0.92 0.89 Yes 0.94 0.89 No
Adiponectin Index∗∗
50(μg/mL) 1.27 1.08 Yes 1.29 1.11 Yes
10 0.99 1.25 No 1.07 0.95 Yes
5 1.02 0.92 Yes 0.94 1.06 No
1 1.19 1.07 Yes 1.03 0.94 Yes
∗Lipogenic Index = [optical density]test/[optical density]DMSO control.
∗∗Adipogenic Index = [adiponectin]test/[adiponectin]TNFα control.
treatment alone at 100mg/kg did not reduce the glucose
concentration, but RIAA : PAC at 1 : 5 signiﬁcantly reduced
glucose concentration from 31.20 ± 1.33mmol/L to 28.92 ±
1.53mmol/L (P = .024; Figure 1(a)). The combined ratio of
1 : 10 did not exhibit a signiﬁcant eﬀect (data now shown).
The rosiglitazone treatment also signiﬁcantly reduced glu-
coseconcentration.However,noneofthetreatments,includ-
ing rosiglitazone, aﬀected insulin concentrations in KK-
Ay/Ta mice (Figure 1(b)). In db/db mice, only rosiglitazone
treatment signiﬁcantly reduced glucose concentration (P<
.001; Figure 1(c)). RIAA treatment at 100mg/kg reduced
insulin concentration from 94.2 ± 7.1pmol/L to 78.4 ±
5.5pmol/L (P = .022), while PAC treatment at 100mg/kg
did not have any eﬀect. The RIAA : PAC at 1 : 5, however,
signiﬁcantly reduced insulin from 104.5 ± 5.7pmol/L to 83.4
± 7.0pmol/L (P = .002), as did the rosiglitazone control
(P = .006) (Figure 1(d)). The combined ratio of 1 : 10 did
not signiﬁcantly aﬀect insulin and glucose concentrations
(data not shown).
3.3. Human Clinical Trial. Given the observed synergistic
eﬀect of RIAA : PAC at 1 : 5 but not at 1 : 10 on glucose
metabolism in 2 mouse models, we chose the 1 : 5 combi-
nation for our clinical trial. A total of 104 individuals were
e n r o l l e d( 3 5f o rA r m1+4 ,3 5f o rA r m2 ,a n d3 4f o rA r m
3) and 91 completed the study (33 for Arm 1 + 4, 29 for
Arm 2, and 29 for Arm 3). Baseline characteristics, fasting
glucose and insulin and their 2-hour postprandial responses,
and serum lipids did not diﬀer by treatment arm (Table 2).
As expected, participants exhibited high cholesterol, LDL,
TG, and elevated blood pressure and were obese. There were
no signiﬁcant diﬀerences among arms at baseline in daily
dietary caloric and nutrient intake except for soluble ﬁber
(Table 2).
Over time, total energy, carbohydrate, total fat, and
saturated fat intake decreased in all arms, but the changes
did not diﬀer among arms (Table 3). Compared to baseline
intake, Arms 1 + 4 (receiving placebo) had an increase
in vegetable, soluble ﬁber, and insoluble ﬁber intake at 8
and/or 12 weeks, Arm 2 (receiving 3 active tablets daily)
had an increase in vegetable intake at 8 weeks, and Arm 3
(receiving 6 active tablets daily) had an increase in soluble
ﬁber and insoluble ﬁber intake at 8 and/or 12 weeks. Over
time,individualsinallarmslostweight,waistcircumference,
and BMI at 8 weeks and 12 weeks compared to baseline
although the degree of changes did not diﬀer among arms.
Somereductionsinsystolicanddiastolicbloodpressurewere
o b s e r v e di nA r m s1+4a n dA r m2( Table 4).
In terms of glucose metabolism (Table 4), Arms 1 and 4
participants showed an increase in fasting glucose at 8 weeks
(P = .008) and 12 weeks (P = .013) compared to baseline;
Arm 2 participants did not show any changes at 8 and 12
weeks; Arm 3 participants showed an increase at 8 weeks
(P = .001) and 12 weeks (P = .014) compared to baseline.
However, these values were within normal physiological
ranges. The 2-hour post-prandial glucose values at 8 weeks
and 12 weeks were similar to baseline in all 3 arms. Fasting
insulin levels remained unchanged over time for Arm 1 + 4,
but were signiﬁcantly reduced at 8 weeks (P = .007) and
12 weeks (P = .045) for Arm 2. For Arm 3, the levels were
also reduced at 8 weeks (P = .017) but not at 12 weeks
(P = .81). The 2-hour post-prandial insulin values exhibited
large variations but generally remained unchanged except
b e i n gh i g h e rf o rA r m1+4a t1 2w e e k s( P = .041).
Of all the assessed lipid parameters (Table 3), serum
TG exhibited the most signiﬁcant diﬀerences over time.
Compared to baseline, the TG level remained unchanged
for Arm 1 + 4, decreased signiﬁcantly at 8 weeks (by
0.55 ± 0.14mmol/L; P<. 001) and 12 weeks (by 0.59
± 0.12mmol/L; P<. 001) for Arm 2, and decreased
signiﬁcantly at 8 weeks (by 0.50 ± 0.18mmol/L; P = .011)
but not 12 weeks (by 0.25 ± 0.24mmol/L; P = .311) for Arm
3. Serum cholesterol was signiﬁcantly reduced in Arm 1 + 4
at 12 weeks (P = .015) and moderately reduced in Arm 3 at
8w e e k s( P = .065). Serum LDL remained unchanged in all
3 arms except for a trend toward reduction in Arm 1 + 4 at
12 weeks (P = .065). Serum HDL also remained unaﬀected
in all 3 arms except for a trend toward reduction in Arm 3
at 8 weeks (P = .062). TG : HDL reﬂected the ﬁndings of
lowered serum TG; a signiﬁcant reduction was observed in
Arm 2 at 8 and 12 weeks. A reduction in the HOMA scores
was observed for Arm 2 at 8 weeks (P = .028).J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 5
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Figure 1: Nonfasting serum glucose and insulin concentration in KK-Ay/Ta mice (a,b) and db/db mice (c,d).
4. Discussion
In the 3T3-L1 preadipocyte diﬀerentiation assay, a validated
model of insulin-sensitizing capacity, the 1 : 5 combination
of RIAA and PAC increased lipid incorporation under
the condition of hyperinsulinemia in a synergistic manner
at all four concentrations tested. This combination also
demonstrated the ability to improve glucose metabolism in
vivo in 2 type 2 diabetes mouse models: nonfasting serum
glucose signiﬁcantly decreased in KK-Ay/Ta mice and non-
fasting serum insulin signiﬁcantly decreased in db/db mice
after administration with RIAA : PAC at 1 : 5. Subjects with
metabolic syndrome who took 100mg RIAA and 500mg
PAC three times daily and followed the AHA Step 1 low-fat
diet for 12 weeks experienced signiﬁcant decreases in fasting
TG and insulin levels compared to individuals who took
placebo and followed the same diet. Subjects in this treat-
mentgroupalsoshowedgreaterreductionsinTG : HDLand
HOMA scores. Taken together, results of these three studies
demonstrate the potential of this synergistic combination
of phytonutrients to favorably modulate dysregulated lipids
and insulin sensitivity in insulin resistance and metabolic
syndrome.
Mean TG levels in the United States have increased in
recent decades, with elevated fasting TG (concentrations of
150mg/dL or higher) now the norm in one out of three
Americans [23]. Out of all the risk factors for metabolic
syndrome, higher fasting TG, along with lower HDL and
abdominal obesity, is the strongest predictor of metabolic
syndromedevelopment[24].Otherriskfactorsformetabolic
syndrome, such as elevated blood pressure and altered
glucose metabolism, diﬀer more by age and sex and are
not necessarily the strongest risk factors. In addition to
predicting the risk of metabolic syndrome and new-onset
diabetes [25], elevated fasting TG has been associated with
1.7 times increased risk for cardiovascular disease [26]. This
increased risk is independent of LDL [27] and even HDL
cholesterol levels [28]. Having both increased fasting TG
levels and a high waist circumference are also independently
associated with various other cardiometabolic risk factors,
including small low-density lipoprotein particles, increased
apolipoprotein B levels, increased insulin levels, reduced
adiponectin concentrations [29], as well as subclinical vas-
cular damage [30].
As research on the clinical and pathophysiological eﬀects
of elevated TG and systemic fatty acids on insulin resis-
tance and metabolic syndrome continues, the traditional
glucocentric perspective is being replaced. The processes
of lipotoxicity and lipoapoptosis, in which the formation
of reactive lipid particles promotes metabolically relevant
cellular dysfunction and programmed cell death, are now
known to be major mediators of insulin resistance, diabetes,
and cardiovascular disease [31]. Unoxidized long-chain fatty
acids overaccumulate, saturating the storage capacity of
adipose tissue and leading to deleterious lipid spillover. The
portal circulation becomes ﬂooded with free fatty acids
at metabolically inappropriate times when free fatty acids
should be oxidized, thus exposing nonadipose tissues to fat
excess. In the liver, muscle, heart, and pancreas, the excess
lipids are driven into pathways which result in lipoapop-
tosis, ultimately leading to organ failure. The additional
dysregulation of glucose homeostasis in combination with6 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Table 2: Baseline anthropometrics, dietary intake, glucose metabolism, and lipid parameters of study participants by treatment arm.
A r m1+4( p l a c e b o ) A r m2( 3t a b l e t s ) A r m3( 6t a b l e t s ) P-Value
Sex
Men 11 12 11
Women 24 23 23
Age(y) 46.0 ±2.24 7 .9 ±2.34 5 .1 ±2.0. 6 5
Weight (kg) 100.1 ±2.79 9 .6 ±2.4 100.9 ±3.0. 9 5
Waist (cm) 108.9 ±2.1 108.9 ± 1.9 109.2 ±2.2. 9 9
BMI (kg/m2)3 5 .0 ±0.73 5 .4 ±0.73 5 .4 ±0.8. 8 9
Total energy (kJ) 8303 ±460 8948 ± 427 8224 ±670 .45
Carbohydrate (g) 232.6 ±13.6 257.6 ±18.8 257.8 ±24.6. 5 6
Protein (g) 81.5 ±4.78 7 .0 ±4.48 5 .5 ±5.3. 7 0
Total fat (g) 81.3 ±5.88 3 .1 ±5.19 3 .4 ±7.4. 3 3
Saturated fat (g) 27.5 ±2.12 7 .5 ±2.13 1 .7 ±2.7. 3 3
Fruit (serving) 2.3 ±0.32 .5 ±0.32 .8 ±0.4. 5 3
Vegetable (serving) 3.1 ±0.33 .4 ±0.33 .2 ±0.2. 6 7
Soluble ﬁber (g) 1.7 ±0.22 .7 ±0.61 .4 ±0.1. 0 3
Insoluble ﬁber (g) 4.4 ±0.45 .0 ±0.74 .2 ±0.4. 5 4
Blood pressure (mmHg)
Systolic 131.0 ±2.6 129.7 ± 2.4 127.5 ±3.0. 6 4
Diastolic 83.7 ±1.48 2 .6 ±1.38 3 .7 ±1.8. 8 3
F. glucose (mmol/L) 5.35 ±0.09 5.50 ± 0.10 5.38 ±0.09 .53
Glucose 2pp (mmol/L) 6.06 ±0.29 7.13 ± 0.37 6.77 ±0.44 .11
F. insulin (pmol/L) 94.7 ±6.5 125.3 ±15.99 9 .2 ±9.9. 1 2
Insulin 2pp (pmol/L) 575.5 ±65.1 820.9 ±132.4 599.4 ±81.8. 1 4
HbA1c, % 5.61 ±0.06 5.68 ± 0.07 5.70 ±0.07 .63
Cholesterol (mmol/L) 5.48 ±0.18 5.41 ± 0.17 5.46 ±0.17 .96
LDL (mmol/L) 3.20 ±0.14 3.10 ± 0.15 3.19 ±0.16 .88
TG (mmol/L) 2.61 ±0.26 2.89 ± 0.25 2.52 ±0.18 .53
HDL (mmol/L) 1.07 ±0.03 1.07 ± 0.03 1.09 ±0.03 .83
Chol : HDL 5.2 ±0.25 .1 ±0.25 .0 ±0.2. 7 4
TG : HDL 5.8 ±0.66 .3 ±0.65 .4 ±0.4. 4 6
excess fatty acids provides an even greater synergistic eﬀect
leadingtolipotoxicity andcelldeath.Therefore,TGandfatty
acids should become a primary target for treating metabolic
syndrome.
Lifestyle modiﬁcation with diet, regular exercise, and
weight control, remains the primary intervention for low-
ering TG [23]a n dh a sp r o v e ne ﬀective in large prospective
studies for prevention and treatment of the metabolic
syndrome [32]. It is to be expected that a majority of persons
will forgo long-term compliance with lifestyle changes alone,
and it is probable that those taking pharmaceuticals will
fail to adequately control the myriad metabolic imbalances
manifest in the syndrome. Due to the high cost of metabolic
syndrome, both in terms of human lives and monetary
expenditures, it seems highly desirable to have safe, eﬀective
natural agents to support treatment.
Animalandclinicalstudieswithanotherhopcompound,
isohumulone, which is structurally similar to RIAA but less
chemically stable [33], have revealed its ability to reduce lev-
elsofplasmaTG,freefattyacids,plasmaglucose,andHbA1c,
improve glucose tolerance, and reduce insulin resistance
[34, 35]. The in vitro and in vivo data from diabetic mouse
models reported in the current study provides evidence for
the hop compound RIAA for the insulin sensitizing capacity.
Though we observed statistically signiﬁcant responses
in terms of TG, TG : HDL, and fasting insulin in subjects
receiving RIAA (100mg) : PAC (500mg) three times daily
at both 8 and 12 weeks, other variables, especially those
related to glucose metabolism, did not improve in this
arm and were actually less favorable in the arm receiving
six tablets daily, as well as in the placebo arm. At least
three explanations may account for this lack of favorable
changes. First, subjects in all three arms had normal baseline
glucose homeostasis—deﬁned as a fasting plasma glucose
level of less than 100mg/dL and a 2-hour oral glucose
tolerance test result of less than 140mg/dL after a 75g
oral glucose load—with no evidence of impaired fasting
glucose or impaired glucose tolerance. After treatment,
fasting glucose remained within normal physiological ranges
for the 3-tablets-daily and placebo arms and increased only
slightly above normal in the 6-tablets-daily arm despite
the statistically signiﬁcant increases from baseline in theJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 7
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placebo and 6-tablets-daily-arms. Because fasting glucose
and glucose tolerance started and remained primarily within
normal physiological ranges, and because changes were
so slight, they may be considered clinically insigniﬁcant.
Second, it has been shown that metabolic parameters such
as fasting glucose are not the primary predictors of the
metabolic syndrome [24] and that insulin sensitivity can
already be substantially decreased within the normal range
of fasting and 2-hour glucose [36]. As the roles of free fatty
acids and insulin resistance in cardiometabolic risk continue
to be reﬁned, it is becoming apparent that treating elevated
TG and associated lipotoxicity is important, independent
of glucose metabolism. In the 3-tablets daily arm, the
combination of normal glucose metabolism with signiﬁcant
improvements in TG and fasting insulin indicates the
possibility that patients were mildly insulin sensitive but had
not yet developed overt problems with glucose homeostasis.
Perhaps extending RIAA/PAC treatment duration beyond
12 weeks or studying patients with more advanced glucose
homeostasis dysregulation at baseline would have achieved
more signiﬁcant results in terms of measures of both
glucose and lipid metabolism. Third, although the subjects’
compliance with dietary and exercise recommendations was
satisfactory, it is possible that the AHA Step 1 (low-fat)
diet, even when combined with these supplemental phy-
tonutrients, was inadequate for producing greater changes
in parameters related to glucose, insulin, or lipids. The
AHA Step 1 diet, primarily intended as the starting point
for treating hypercholesterolemia, restricts total fat to no
more than 30 percent of total calories, saturated fat to no
more than 10 percent of total calories, and cholesterol to
less than 300mg/day [37]. It has been found to lower both
serum total cholesterol and LDL cholesterol [38] but has
also been associated with lowering serum HDL cholesterol
[39] as well as with nutritional inadequacies [40] and has
since been replaced by new, more comprehensive AHA
dietary recommendations as part of Therapeutic Lifestyle
Changes [41]. More comprehensive diets, such as those
which reduce glycemic load and increase ﬁber, may be
required in combination with supplemental phytonutrients
such as RIAA : PAC in order to achieve more substantial
reductions in established risk markers for cardiovascular
disease and type 2 diabetes.
The favorable results for TG and fasting insulin observed
in the arm receiving RIAA : PAC three times daily did not
carry over to those receiving the tablets six times daily.
The plateau may have simply been reached using the lower
dosage method although this does not explain the fact that
we did not observe even similar beneﬁts in the higher-
dose arm. Alternate explanations include the possibility of
an absorption issue at this higher dose, or, more likely,
could be related to the slightly higher serum TG and fasting
insulin levels observed in the 3-tablets-daily arm at baseline.
These mildly higher values may be more likely to respond
to this phytonutrient combination, regardless of the dose.
Both pharmacokinetic studies as well as larger controlled
studies in patients with more advanced hypertriglyceridemia
and glucose dysregulation at baseline would provide further
insight into the dosage issue. The current data indicates that
three tablets daily provide maximum physiological impact,
and higher oral doses do not increase clinical beneﬁt.
5. Conclusions
Thecontinuingepidemicofmetabolicsyndrome,whichsub-
stantially increases the risk of type II diabetes and cardiovas-
cular disease, calls for novel, eﬀective therapeutic approaches
beyond pharmaceuticals and lifestyle modiﬁcation. The
addition of certain phytochemicals such as RIAA from hops
and PAC from acacia to dietary and lifestyle modiﬁcation
has the potential to more favorably modulate insulin sig-
naling and to decrease the deleterious eﬀects of lipotoxicity
which characterize metabolic syndrome. We showed that the
speciﬁc combination of RIAA : PAC (1 : 5) synergistically
increased TG content in 3T3-L1 adipocytes under conditions
of hyperinsulinemia and increased adiponectin secretion in
cells treated with TNF-α. Serum glucose or insulin concen-
trations in KK-Ay/Ta and db/db mice were reduced by three-
dayoraltreatmentwithsuchcombinationat100mg/kgbody
weightmorethanbytreatmentswithindividualcompounds.
Daily supplementation with 300mg RIAA and 1500mg
PAC in addition to lifestyle modiﬁcation including dietary
alteration reduces serum TG, TG : HDL, and fasting insulin
signiﬁcantly more than diet and lifestyle modiﬁcation alone
in patients with features of the metabolic syndrome. This
phytonutrient combination provides a potential therapy for
correcting or modulating dysregulated lipids and improving
insulin sensitivity in metabolic syndrome.
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